As a calcium channel blocker, verapamil gel slows or stops the progression of Peyronie’s disease, reduces Peyronie’s plaque, and reduces or eliminates the symptoms of the condition, states PDLabs. It is a topical, non-invasive treatment for fibrotic tissue disorders, such as Peyronie’s disease.
Peyronie’s disease is a condition in which fibrous scar tissue develops inside the penis and causes curved, painful erections, according to Mayo Clinic. This scar tissue forms in the tunica albuginea, explains the Male Health Center. Normally, the elastic tissue of the penis expands and elongates into a straight erection. With Peyronie’s disease, the inelasticity of the plaque forces the penis to curve.
The main components of Peyronie’s plaque are collagen, fibronectin and glycosaminoglycans, which fibroblast cells produce, explains PDLabs. The process that releases these components out of the fibroblast cells requires calcium. Verapamil, as a calcium channel blocker, decreases the production of fibronectin and collagen and their release from the fibroblast. It also impairs the increase of fibroblasts. The application of the gel in the early stages reduces the severity of the condition.
Fibroblasts produce an enzyme called collagenase, which breaks down or remodels the excess collagen that constitutes Peyronie’s plaque, states PDLabs. Verapamil increases collagenase activity, which causes already-formed and stable Peyronie’s plaque to remodel into healthy, elastic tissue. This reduces or eliminates the symptoms of Peyronie’s disease. This collagenase-increasing activity of verapamil is still theoretical.